Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.
about
Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha2C-adrenoceptorsEstrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteriesRegulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenonRaynaud's Phenomenon: A Brief Review of the Underlying MechanismsIntracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90Molecular determinants of the human α2C-adrenergic receptor temperature-sensitive intracellular trafficDistinct cAMP signaling pathways differentially regulate alpha2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells.Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough.Regulation of G protein-coupled receptor export trafficking.Mechanisms of Raynaud's disease.The alpha2C-adrenoceptor deletion322-325 variant and cold-induced vasoconstriction.The association between vibration and vascular injury in rheumatic diseases: a review of the literature.A vascular mechanistic approach to understanding Raynaud phenomenon.Herbal Prescription, DSGOST, Prevents Cold-Induced RhoA Activation and Endothelin-1 Production in Endothelial Cells.Role of digital artery adrenoceptors in Raynaud's disease.Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries.Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.
P2860
Q23909443-609AABE1-00E7-4EAB-9F0D-C2EDD1B67C42Q23909444-BA3A16B1-09D1-4453-9C00-19965B495BB4Q24170159-8ACB2CC6-48DD-4CCD-970F-E18E1A90C981Q28067805-FD360C42-4411-4143-8AF1-C620F82F22C8Q28389791-F8B4C9EB-4757-411E-A25C-FE31F2AB1BA5Q28390844-18FC8E8A-72BD-4DD8-80BB-7FB87E456A57Q28392425-1041D4E2-0082-4B73-87A4-4ED979EA96C4Q34345511-65A49C6E-57D8-4BD8-8962-8B6A0A22F805Q34744859-06582D41-65AB-4D43-8445-92646E9C3BE7Q35827970-27D3D8AE-D59E-46CC-A64F-8586B656AF51Q36380983-FE52D702-2CE1-493A-8B36-2BEDCEDF8C58Q37337249-B496216A-A25C-47D2-AB0B-4D58B44A45FCQ38238935-9D06BCFE-EBA7-46B9-B16F-6C6983266171Q38299133-DAFA3FD9-BDAA-4248-9968-DF58FC3021C8Q39197971-EEEE9289-B5B6-42B7-B2D0-1BA613921459Q39464867-F6A5F645-5DEC-48B7-BD72-2477CFB4A637Q39549761-75E050CF-671D-4D43-AE0F-7460348FA201Q39702720-B2871498-7407-4D6A-B6D7-2C6915A2F03CQ40447301-B3120162-DDDC-4A89-AB93-BC79E15AB4DFQ44334663-881BB1CE-413C-4BB5-8F54-C3F85DC6253EQ44898221-A944AC08-0307-4AA3-83CA-22FCA74E892E
P2860
Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@en
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@nl
type
label
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@en
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@nl
prefLabel
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@en
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@nl
P2093
P356
P1433
P1476
Blockade of vasospastic attack ...... idiopathic Raynaud's disease.
@en
P2093
P304
P356
10.1161/01.CIR.92.6.1448
P407
P577
1995-09-01T00:00:00Z